Investigating flavonoids as m olecular templates for the design of small-molecule inhibitors of cell signaling

Journal of Food Science

Volumn 78, Issue 12, 2013, Pages

  Wright, Bernice ^a   Tindall, Marcus J ^a   Lovegrove, Julie A ^a   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Antiplatelet drugs; Cardiovascular disease; Drug design; Flavonoid molecular templates; Flavonoids; Rational screening

Indexed keywords

ANTHOCYANIN; ANTITHROMBOCYTIC AGENT; FLAVONOID; HYDROXYBENZOIC ACID DERIVATIVE; PHENOLIC ACID; POLYPHENOL; STILBENE DERIVATIVE;

CARDIOVASCULAR DISEASES; DRUG DESIGN; DRUG EFFECTS; HUMAN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

ANTIPLATELET DRUGS; CARDIOVASCULAR DISEASE; DRUG DESIGN; FLAVONOID MOLECULAR TEMPLATES; FLAVONOIDS; RATIONAL SCREENING;

ANTHOCYANINS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG DESIGN; FLAVONOIDS; HUMANS; HYDROXYBENZOATES; PLATELET AGGREGATION INHIBITORS; POLYPHENOLS; SIGNAL TRANSDUCTION; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

MLCS; MLOWN;

EID: 84890150338     PISSN: 00221147     EISSN: 17503841     Source Type: Journal    
DOI: 10.1111/1750-3841.12293     Document Type: Article

References (32)

1. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H, Payrastre B. 1997. Relationship between flavonoids structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53(11):1649-57.
2. Bain J, McLauchlan H, Elliott M, Cohen P. 2003. The selectivity of protein kinase inhibitors: an update. Biochem J 371(Pt 1):199-204.
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 (3):297-315.
4. Byun S, Park J, Lee E, Lim S, Yu JG, Lee SJ, Chen H, Dong Z, Lee KW, Lee HJ. 2013. Src kinase is a direct target of apigenin against UVB-induced skin inflammation. Carcinogenesis 34(2):397-405.
5. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, Zhou W, Huang J, Tang Y. 2012. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8(5):e1002503.
6. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. 2002. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 99(1):137-44.
7. Cuccioloni M, Mozzicafreddo M, Bonfili L, Cecarini V, Eleuteri AM, Angeletti M. 2009. Natural occurring polyphenols as template for drug design. Focus on serine proteases. Chem Biol Drug Des 74 (1):1-15.
8. Daminelli S, Haupt VJ, Reimann M, Schroeder M. 2012. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. Integr Biol (Camb) 4(7):778-88.
9. Davies SP, Reddy H, Caivano M, Cohen P. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351(Pt 1):95-105.
10. Farkas IJ, Korcsmaros T, Kovacs IA, Mihalik A, Palotai R, Simko GI, Szalay KZ, Szalay-Beko M, Vellai T, Wang S, Csermely P. 2011. Network-based tools for the identification of novel drug targets. Sci Signal 4(173). doi: 10.1126/scisignal.2001950.
11. Gibbins JM. 2004. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117(Pt 16):3415-25.
12. Gibbins J, Asselin J, Farndale R, Barnes M, Law CL, Watson SP. 1996. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem 271(30):18095-9.
13. Gibbins JM, Briddon S, Shutes A, van Vugt MJ, de Winkel JGJ, Saito T, Watson SP. 1998. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 273(51):34437-43.
14. Goettert M, Schattel V, Koch P, Merfort I, Laufer S. 2010. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids. Chembiochem 11(18):2579-88.
15. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. 2007. Characterisation of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6(1):163-72.
16. Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, Lin L, Zhu W, Ding J, Jiang H, Liu H. 2009. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors. Eur J Med Chem 44(5):1982-9.
17. Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. 2003. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signalling pathway. J Thromb Haemost 1(5):1079-88.
18. Hwang MK, Kang NJ, Heo YS, Lee KW, Lee HJ. 2009. Fyn kinase is a direct target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha. Biochem Pharmacol 77(7):1213-22.
19. Jonnalagadda D, Izu LT, Whiteheart SW. 2012. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood 120(26):5209-16.
20. Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, Bode AM, Bowden GT, Lee HJ, Dong Z. 2008. Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 68(14):6021-9.
21. Jung SK, Lee KW, Kim HY, Oh MH, Byun S, Lim SH, Heo YS, Kang NJ, Bode AM, Dong Z, sss 2010. Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf. Biochem Pharmacol 79(10):1455-61.
22. Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, Liu QF, Lin LP, Geng MY, Jiang H, Zhao WM, Ding J, Ye Y. 2008. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. J Med Chem 51(15):4419-29.
23. Matter WF, Brown RF, Vlahos CJ. 1992. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun 186(2):624-31.
24. Mccarty OJT, Calaminus SDJ, Berndt MC, Machesky M, Watson SP. 2006. von Willebrand factor mediates platelet spreading through glycoprotein Ib and aIIbb3 in the presence of botrocetin and ristocetin, respectively. J Thromb Haemost 4(6):1367-78.
25. Picq M, Prigent AF, Nemoz G, Andre AC, Pacheco H. 1982. Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain. J Med Chem 25(10):1192-8.
26. Thanigaimalai P, Le Hoang TA, Lee KC, Sharma VK, Bang SC, Yun JH, Roh E, Kim Y, Jung SH. 2010. Synthesis and evaluation of novel chromone analogs for their inhibitory activity against interleukin-5. Eur J Med Chem 45(6):2531-6.
27. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241-8.
28. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. 2000. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine. Mol Cell 6(4):909-19.
29. Wang X, Xu X, Li Y, Li X, Tao W, Li B, Wang Y, Yang L. 2013. Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr Biol (Camb) 5(2):351-71.
30. Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA, Gibbins JM. 2010. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharmacol 159(6):1312-25.
31. Yu H, Chen J, Xu X, Li Y, Zhao H, Fang Y, Li X, Zhou W, Wang W, Wang Y. 2012. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoSOne 7(5):e37608. doi: 10.1371/journal.pone.0037608.
32. Zhang L, Pang E, Loo RR, Rao J, Go VL, Loo JA, Lu QY. 2011. Concomitant inhibition of HSP90, its mitochondrial localised homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAF-II cells. Proteomics 11(24):4638-47. doi: 10.1002/pmic.201100242.